drugset / Trial / NCT00605306

Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma

NCT00605306

Phase 2 Completed 28 enrolled Novartis Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will investigate the safety and tolerability of indacaterol maleate/mometasone furoate via the Twisthaler device after 14 days treatment in patients with mild to moderate asthma.

Timeline

Start
2008-01
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 500 ug Inhaled
Subject Mometasone Other / unclassified 800 ug Inhaled

Indications